Caplin Point Laboratories quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	610	510	+19.6%
EBITDA	213	178	+20.1%
EBITDA margin	35.0%	34.8%	+0.1 pts
Profit before tax	225	184	+22.1%
Net profit	179	151	+18.8%
EPS	₹23.27	₹20.10	+15.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	610	600	543	534	510	502	493	483	459	453	436	410	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	33.6	28.4	33.7	30.4	23.1	25.7	31.4	20.8	18.6	17.3	17.2	20.4
	644	629	576	564	533	528	524	504	478	471	453	430
	107	102	89.2	92.3	73.5	60.8	59.8	69.2	63.7	57.9	51.0	66.8
	196	209	128	122	114	139	139	122	74.5	122	180	129
	−58.2	−66.1	−2.1	−3.7	8.2	1.6	−3.9	−2.7	47.4	11.7	−40.6	−32.1
	54.1	52.6	49.8	47.2	43.2	46.5	46.8	44.3	40.2	36.8	36.7	35.1
	0.2	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2
	21.6	18.8	19.3	18.4	16.3	17.0	16.2	16.8	16.0	16.4	13.9	11.8
	97.6	98.3	88.2	87.3	94.1	86.7	88.6	85.2	81.5	79.9	66.4	73.5
	419	415	373	363	349	352	347	335	323	325	307	285
	213	204	190	189	178	168	162	165	152	145	142	137
	192	185	170	171	161	151	146	148	136	129	128	126
Profit
	225	213	204	201	184	177	177	169	154	146	145	146
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
	225	213	204	201	184	177	177	169	154	146	145	146
	46.2	41.0	35.6	36.5	33.1	29.3	34.2	32.5	29.4	20.6	26.0	30.7
	−0.1	−0.5	2.4	4.2	0.6	2.1	3.0	5.2	0.1	4.2	−0.4	−0.8
	46.1	40.6	38.0	40.8	33.7	31.4	37.2	37.7	29.5	24.8	25.6	29.9
	−0.0	0.0	−0.0	0.0	0.0	0.1	−0.0	−0.1	0.0	0.0	0.0	0.1
	179	173	166	160	151	145	140	131	125	121	120	116
	179	173	166	160	151	145	140	131	125	121	120	116
	−1.9	76.9	16.8	47.5	0.4	−1.8	22.8	1.3	4.7	3.3	0.9	9.7
	177	250	183	208	151	144	163	132	130	124	121	126
	177	170	164	154	153	141	139	131	124	122	117	115
	2.2	2.8	2.0	5.8	−2.0	2.7	1.1	0.0	1.0	−0.4	2.6	1.3
Per share
	₹23.27	₹22.38	₹21.56	₹20.32	₹20.10	₹18.75	₹18.28	₹17.22	₹16.32	₹16.01	₹15.44	₹15.13
	₹23.21	₹22.31	₹21.51	₹20.25	₹20.03	₹18.69	₹18.19	₹17.12	₹16.24	₹15.90	₹15.39	₹15.06
Other comprehensive income — detail
	−1.9	76.9	16.8	47.5	0.4	−1.8	—	—	—	—	—	—
	—	−0.1	−0.7	1.3	—	−0.2	0.0	0.4	—	−0.5	0.0	0.5
	0.0	0.0	0.0	0.3	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.1	0.0	−0.1	0.0	0.1
	−1.9	77.0	17.6	46.5	0.4	−1.5	22.8	1.0	4.7	3.7	0.8	9.3
	175	247	181	202	153	—	162	132	129	125	117	—
	2.2	2.8	2.0	5.8	−2.0	—	1.1	0.0	1.0	−0.4	2.6	—
Per share — as-filed variants
	₹23.27	₹22.38	₹21.56	₹20.32	₹20.10	₹18.75	₹18.28	₹17.22	₹16.32	₹16.01	₹15.44	₹15.13
	₹23.21	₹22.31	₹21.51	₹20.25	₹20.03	₹18.69	₹18.19	₹17.12	₹16.24	₹15.90	₹15.39	₹15.06
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	365	355	328	324	315	301	298	294	273	262	245	246
	59.8%	59.2%	60.4%	60.6%	61.7%	60.0%	60.4%	60.9%	59.6%	57.8%	56.3%	60.0%
Adjusted (ex-exceptional items) — derived
	225	213	204	201	184	177	177	169	154	146	145	146
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
	179	173	166	160	151	145	140	131	125	121	120	116
	₹23.27	₹22.38	₹21.56	₹20.32	₹20.10	₹18.75	₹18.28	₹17.22	₹16.32	₹16.00	₹15.44	₹15.13

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CAPLIPOINT₹2,376.10

Caplin Point Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAJANTPHARM ERIS GLAND BLUEJET CONCORDBIO ACUTAAS EMCURE GRANULESMcap ₹18,058 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	410.1	435.5	453.2	459.0	483.1	493.0	502.5	510.2	534.0	542.8	600.2	610.4
Other Income	20.4	17.2	17.3	18.6	20.8	31.4	25.7	23.1	30.4	33.7	28.4	33.6
Total Income	430.5	452.7	470.5	477.5	503.9	524.3	528.2	533.4	564.4	576.5	628.5	643.9
Expenses
+ Cost of Materials Consumed	66.8	51.0	57.9	63.7	69.2	59.8	60.8	73.5	92.3	89.2	102.1	107.1
+ Purchases of Stock-in-Trade	129.3	179.8	121.8	74.5	122.3	139.4	138.8	113.5	121.7	128.0	209.0	196.4
+ Changes in Inventories	-32.1	-40.6	11.7	47.4	-2.7	-3.9	1.6	8.2	-3.7	-2.1	-66.1	-58.2
+ Employee Benefit Expense	35.1	36.7	36.8	40.2	44.3	46.8	46.5	43.2	47.2	49.8	52.6	54.1
+ Finance Costs	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.4	0.2
+ Depreciation & Amortisation	11.8	13.9	16.4	16.0	16.8	16.2	17.0	16.3	18.4	19.3	18.8	21.6
+ Other Expenses	73.5	66.4	79.9	81.5	85.2	88.6	86.7	94.1	87.3	88.2	98.3	97.6
Total Expenses	284.6	307.3	324.5	323.2	335.3	347.1	351.6	348.9	363.4	372.5	415.1	418.7
EBITDA	137.4	142.3	145.2	151.8	164.8	162.3	168.1	177.8	189.2	189.7	204.2	213.5
EBIT	125.6	128.4	128.8	135.9	148.0	146.1	151.0	161.5	170.8	170.4	185.4	191.9
Profit
PBT before Exceptional Items	145.9	145.4	146.0	154.4	168.6	177.3	176.6	184.4	201.0	203.9	213.4	225.2
+ Exceptional Items	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pretax Income	145.9	145.4	146.0	154.4	168.6	177.3	176.6	184.4	201.0	203.9	213.4	225.2
+ Current Tax	30.7	26.0	20.6	29.4	32.5	34.2	29.3	33.1	36.5	35.6	41.0	46.2
+ Deferred Tax	-0.8	-0.4	4.2	0.1	5.2	3.0	2.1	0.6	4.2	2.4	-0.5	-0.1
Tax Expense	29.9	25.6	24.8	29.5	37.7	37.2	31.4	33.7	40.8	38.0	40.6	46.1
+ Share of Associates & JVs	0.1	0.0	0.0	0.0	-0.1	-0.0	0.1	0.0	0.0	-0.0	0.0	-0.0
Net Income	116.1	119.8	121.2	124.9	130.8	140.1	145.3	150.8	160.2	165.9	172.9	179.1
+ Net Income — Continuing Ops	116.0	119.8	121.2	124.9	130.9	140.1	145.2	150.7	160.2	165.9	172.9	179.1
+ Other Comprehensive Income	9.7	0.9	3.3	4.7	1.3	22.8	-1.8	0.4	47.5	16.8	76.9	-1.9
Total Comprehensive Income	125.8	120.7	124.5	129.6	132.1	162.9	143.5	151.1	207.8	182.7	249.8	177.2
Net Income to Common	114.9	117.2	121.6	124.0	130.8	139.0	140.8	152.8	154.5	163.9	170.1	176.9
Minority Interest	1.3	2.6	-0.4	1.0	0.0	1.1	2.7	-2.0	5.8	2.0	2.8	2.2
Per Share
Basic EPS	15.13	15.44	16.01	16.32	17.22	18.28	18.75	20.10	20.32	21.56	22.38	23.27
Diluted EPS	15.06	15.39	15.90	16.24	17.12	18.19	18.69	20.03	20.25	21.51	22.31	23.21
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-1.8	0.4	47.5	16.8	76.9	-1.9
+ Items NOT to be Reclassified to P&L	0.5	0.0	-0.5	—	0.4	0.0	-0.2	—	1.3	-0.7	-0.1	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.3	0.0	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.0	-0.1	0.0	0.1	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	9.3	0.8	3.7	4.7	1.0	22.8	-1.5	0.4	46.5	17.6	77.0	-1.9
Comprehensive Income — Owners of Parent	—	117.2	124.8	128.7	132.1	161.8	—	153.2	202.0	180.7	247.0	175.1
Comprehensive Income — Non-controlling Interests	—	2.6	-0.4	1.0	0.0	1.1	—	-2.0	5.8	2.0	2.8	2.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	15.13	15.44	16.01	16.32	17.22	18.28	18.75	20.10	20.32	21.56	22.38	23.27
Diluted EPS — Continuing Operations	15.06	15.39	15.90	16.24	17.12	18.19	18.69	20.03	20.25	21.51	22.31	23.21
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	246.0	245.4	261.9	273.5	294.3	297.6	301.3	315.0	323.7	327.6	355.2	365.2
Gross Margin %	59.98	56.35	57.78	59.59	60.91	60.37	59.96	61.73	60.62	60.36	59.18	59.83
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	145.9	145.4	146.0	154.4	168.6	177.3	176.6	184.4	201.0	203.9	213.4	225.2
− Exceptional Items (reconciliation)	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	116.1	119.8	121.2	124.9	130.8	140.1	145.3	150.8	160.2	165.9	172.9	179.1
EPS Adj	15.13	15.44	16.00	16.32	17.22	18.28	18.75	20.10	20.32	21.56	22.38	23.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2	15.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Caplin Point Laboratories quarterly results

Caplin Point Laboratories (NSE: CAPLIPOINT) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹177 crore, up 15.8% from ₹153 crore in Q1 FY26 and up 4.0% from ₹170 crore in Q4 FY26. Revenue from operations was ₹610 crore, up 19.6% year on year and up 1.7% from the previous quarter.

Q2 FY26 results (a year earlier): 5 November 2025
Q1 FY27 results (the latest): 12 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹177 Cr+15.8% vs Q1 FY26+4.0% vs Q4 FY26
Q1 FY27 revenue: ₹610 Cr+19.6% vs Q1 FY26+1.7% vs Q4 FY26
Q1 FY27 operating margin: 31.4%−0.2 pts vs Q1 FY26+0.5 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹154 CrRevenue ₹534 Cr
Q1 FY27 EPS (basic): ₹23.27

Questions

When will Caplin Point Laboratories announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 5 November 2025.

What will Caplin Point Laboratories' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹154 crore and revenue from operations ₹534 crore. The latest quarter, Q1 FY27, had a net profit of ₹177 crore and revenue of ₹610 crore.

What was Caplin Point Laboratories' revenue in FY26?

Revenue from operations was ₹2,187 crore in FY26 (April 2025–March 2026), up 12.9% from ₹1,937 crore in FY25. It was ₹1,694 crore in FY24 and ₹1,467 crore in FY23: up 49.1% over three years, 14.2% a year on average.

What were Caplin Point Laboratories' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹177 crore, up 15.8% from ₹153 crore in Q1 FY26 and up 4.0% from ₹170 crore in Q4 FY26. Revenue from operations was ₹610 crore, up 19.6% year on year and up 1.7% from the previous quarter.

How has Caplin Point Laboratories' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹154 crore in Q2 FY26, ₹164 crore in Q3 FY26, ₹170 crore in Q4 FY26 and ₹177 crore in Q1 FY27. That is ₹665 crore over the four quarters, up 18.1% from ₹563 crore in the four quarters before. Revenue from operations: ₹534 crore, ₹543 crore, ₹600 crore and ₹610 crore.

What was Caplin Point Laboratories' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹641 crore in FY26 (April 2025–March 2026), up 13.8% from ₹563 crore in FY25. It was ₹457 crore in FY24 and ₹376 crore in FY23: up 70.4% over three years, 19.4% a year on average.

Where do these Caplin Point Laboratories figures come from?

From Caplin Point Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.